257 related articles for article (PubMed ID: 23643839)
1. Activator or inhibitor? GSK-3 as a new drug target.
Takahashi-Yanaga F
Biochem Pharmacol; 2013 Jul; 86(2):191-9. PubMed ID: 23643839
[TBL] [Abstract][Full Text] [Related]
2. Roles of Glycogen Synthase Kinase-3 (GSK-3) in Cardiac Development and Heart Disease.
Takahashi-Yanaga F
J UOEH; 2018; 40(2):147-156. PubMed ID: 29925734
[TBL] [Abstract][Full Text] [Related]
3. [A new target for diabetes therapy: advances in the research of glycogen synthase kinase-3 inhibitors].
Liu SN; Shen ZF
Yao Xue Xue Bao; 2007 Dec; 42(12):1227-31. PubMed ID: 18338632
[TBL] [Abstract][Full Text] [Related]
4. Pharmacological inhibitors of glycogen synthase kinase 3.
Meijer L; Flajolet M; Greengard P
Trends Pharmacol Sci; 2004 Sep; 25(9):471-80. PubMed ID: 15559249
[TBL] [Abstract][Full Text] [Related]
5. Effects of mutations in Wnt/β-catenin, hedgehog, Notch and PI3K pathways on GSK-3 activity-Diverse effects on cell growth, metabolism and cancer.
McCubrey JA; Rakus D; Gizak A; Steelman LS; Abrams SL; Lertpiriyapong K; Fitzgerald TL; Yang LV; Montalto G; Cervello M; Libra M; Nicoletti F; Scalisi A; Torino F; Fenga C; Neri LM; Marmiroli S; Cocco L; Martelli AM
Biochim Biophys Acta; 2016 Dec; 1863(12):2942-2976. PubMed ID: 27612668
[TBL] [Abstract][Full Text] [Related]
6. Glycogen synthase kinase-3 beta (GSK-3β) signaling: Implications for Parkinson's disease.
Golpich M; Amini E; Hemmati F; Ibrahim NM; Rahmani B; Mohamed Z; Raymond AA; Dargahi L; Ghasemi R; Ahmadiani A
Pharmacol Res; 2015 Jul; 97():16-26. PubMed ID: 25829335
[TBL] [Abstract][Full Text] [Related]
7. Glycogen synthase kinase 3 in Wnt signaling pathway and cancer.
Tejeda-Muñoz N; Robles-Flores M
IUBMB Life; 2015 Dec; 67(12):914-22. PubMed ID: 26600003
[TBL] [Abstract][Full Text] [Related]
8. Pancreastatin, a chromogranin-A-derived peptide, inhibits insulin-stimulated glycogen synthesis by activating GSK-3 in rat adipocytes.
González-Yanes C; Sánchez-Margalet V
Biochem Biophys Res Commun; 2001 Nov; 289(1):282-7. PubMed ID: 11708813
[TBL] [Abstract][Full Text] [Related]
9. Glycogen synthase kinase-3 (GSK-3) inhibitors reach the clinic.
Medina M; Castro A
Curr Opin Drug Discov Devel; 2008 Jul; 11(4):533-43. PubMed ID: 18600569
[TBL] [Abstract][Full Text] [Related]
10. Glycogen synthase kinase 3 (GSK-3) inhibitors as new promising drugs for diabetes, neurodegeneration, cancer, and inflammation.
Martinez A; Castro A; Dorronsoro I; Alonso M
Med Res Rev; 2002 Jul; 22(4):373-84. PubMed ID: 12111750
[TBL] [Abstract][Full Text] [Related]
11. The interaction of glycogen synthase kinase-3 (GSK-3) with the cell cycle.
Ryves WJ; Harwood AJ
Prog Cell Cycle Res; 2003; 5():489-95. PubMed ID: 14593744
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of glycogen synthase kinase-3.
Ougolkov AV; Billadeau DD
Methods Mol Biol; 2008; 468():67-75. PubMed ID: 19099246
[TBL] [Abstract][Full Text] [Related]
13. Glycogen synthase kinases: Moonlighting proteins with theranostic potential in cancer.
Nagini S; Sophia J; Mishra R
Semin Cancer Biol; 2019 Jun; 56():25-36. PubMed ID: 29309927
[TBL] [Abstract][Full Text] [Related]
14. Natural and synthetic bioactive inhibitors of glycogen synthase kinase.
Khan I; Tantray MA; Alam MS; Hamid H
Eur J Med Chem; 2017 Jan; 125():464-477. PubMed ID: 27689729
[TBL] [Abstract][Full Text] [Related]
15. Sequential phosphorylation of insulin receptor substrate-2 by glycogen synthase kinase-3 and c-Jun NH2-terminal kinase plays a role in hepatic insulin signaling.
Sharfi H; Eldar-Finkelman H
Am J Physiol Endocrinol Metab; 2008 Feb; 294(2):E307-15. PubMed ID: 18029441
[TBL] [Abstract][Full Text] [Related]
16. Characterisation of the phosphorylation of beta-catenin at the GSK-3 priming site Ser45.
Hagen T; Vidal-Puig A
Biochem Biophys Res Commun; 2002 Jun; 294(2):324-8. PubMed ID: 12051714
[TBL] [Abstract][Full Text] [Related]
17. GSK-3: tricks of the trade for a multi-tasking kinase.
Doble BW; Woodgett JR
J Cell Sci; 2003 Apr; 116(Pt 7):1175-86. PubMed ID: 12615961
[TBL] [Abstract][Full Text] [Related]
18. Glycogen synthase kinase 3 (GSK-3) inhibitors: a patent update (2014-2015).
Palomo V; Martinez A
Expert Opin Ther Pat; 2017 Jun; 27(6):657-666. PubMed ID: 27828716
[TBL] [Abstract][Full Text] [Related]
19. Glycogen synthase kinase 3 as an anticancer drug target: novel experimental findings and trends in the design of inhibitors.
Osolodkin DI; Palyulin VA; Zefirov NS
Curr Pharm Des; 2013; 19(4):665-79. PubMed ID: 23016861
[TBL] [Abstract][Full Text] [Related]
20. Targeting GSK-3: a promising approach for cancer therapy?
Ougolkov AV; Billadeau DD
Future Oncol; 2006 Feb; 2(1):91-100. PubMed ID: 16556076
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
